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Background: Problematic hypoglycaemia is a significant problem among people with insulin-treated type 1 and 2
diabetes mellitus, which adversely affects quality of life and leads to high societal costs. Blood glucose awareness
training (BGAT) is a psycho-educational group intervention that has shown to be effective but difficult to implement in
clinical practice, due to its demanding nature. The aim of this study is to evaluate the cost-effectiveness of the
HypoAware intervention that has its roots in BGAT and helps patients to effectively recognize, treat and prevent
hypoglycaemia, while also focussing on the psychosocial consequences of living with the constant risk of
hypoglycaemia, both for patients and their significant others.
Methods/design: An economic evaluation will be conducted alongside a cluster-randomised controlled trial in eight
hospitals in the Netherlands. We aim to include 154 participants who will either receive HypoAware or care as usual.
HypoAware consists of three group sessions and is combined with two online modules. The primary clinical outcome
is severe hypoglycaemia. Secondary outcomes include mild hypoglycaemia, hypoglycaemia awareness, fear of
hypoglycaemia, diabetes distress, anxiety and depression, health-related quality of life, diabetes-specific self-efficacy and
HbA1c. Utilities will be measured using the EQ-5D-5 L questionnaire. Costs will be measured from a societal
perspective and include health care utilization, medication and lost productivity costs. Measurements will be
performed at baseline, 2, 4, and 6 months to compare both groups, and an additional 12 months for the intervention
group only. Process outcomes will be gathered after every group meeting via telephone/email contact with health
care professionals and via the online environment.
Discussion: HypoAware is expected to significantly reduce episodes of severe hypoglycaemia, with subsequent
beneficial effects on psychosocial outcomes and health care costs. When proven cost-effective, HypoAware will be
incorporated in the clinical guidelines of Dutch diabetes care.
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Hypoglycaemia is the most common adverse event associ-
ated with insulin treatment in type 1 (T1DM) and type 2
diabetes (T2DM) and causes morbidity, a significant
reduction in quality of life, and even death [1–3].
Hypoglycaemia can lead to high costs due to increased
health care consumption and work productivity loss [1, 4].
Psycho-educational interventions, like Blood Glucose
Awareness Training (BGAT), aimed at reducing and pre-
venting hypoglycaemia are effective [5], but are demand-
ing on clinics’ resources, health care professionals and
people with diabetes. Current economic climate demands
a cost-effective approach. Therefore, we developed a brief
group intervention based on key ingredients of BGAT,
called HypoAware. We combined three group sessions of
2.5 h each with an online learning environment, to main-
tain quality and improve attractiveness, while keeping
costs at a minimum.
We have previously conducted a multi-centre pilot
study of HypoAware in people with T1DM and T2DM
and problematic hypoglycaemia doi: 10.1111/dme.12876.
This study demonstrated the intervention’s feasibility
and acceptability. Continuing on this pilot study, we de-
signed a two-arm cluster-randomised controlled trial
comparing HypoAware with care as usual. In addition to
health-related effectiveness, cost-effectiveness will also
be assessed, since this will inform policy and decision
makers in diabetes care about the cost/benefit ratio of
HypoAware.
This study aims to evaluate the effectiveness and
cost-effectiveness of a brief blended psycho-educational
intervention called HypoAware, aimed at reducing
hypoglycaemia-related problems in people with T1DM
and T2DM in comparison with usual care.Methods/design
Design
An economic evaluation from a societal perspective
will be performed alongside a two-arm multi-centre,
cluster-randomised controlled trial with follow up
measurements at 2, 4 and 6 months for both groups.
Additionally a 12 months follow-up measurement will
take place in the intervention group only to analyse
long-term effects over time.Ethical approval
The study protocol was approved by the Ethics Commit-
tee of the VU University Medical Centre certified by the
Central Committee on Research involving Human Sub-
jects in the Netherlands (NL47354.029.13, registration
number 2014.007). We will obtain written informed con-
sent from all participants.Setting
The study will be carried out in eight self-selected out-
patient diabetes clinics in the Netherlands. The diabetes
care teams in these clinics will conduct the recruitment
and intervention phase. All teams have appointed a local
coordinator. The study coordinator (SR) will be in close
contact with the local coordinators throughout the study.
Randomisation
Cluster randomisation will be done prior to recruitment
of participants at the level of the participating clinics to
avoid contamination within the clinics. The participants
in the control group receive the intervention after the
6 months follow-up as an incentive to participate. Ran-
dom allocation will be performed by two members of
the study team, who randomly select notes from two
opaque envelopes, one with the eight names of the
clinics and one with four notes with ‘intervention’ and
four notes with ‘control’. Participants will be allocated
based on the clinic where they are registered.
Participants
Persons are eligible for this study if they are 18 years or
older, are treated for T1DM or T2DM in an outpatient
setting, perform at least three multiple daily insulin in-
jections a day or are on continuous subcutaneous insulin
infusion (pump therapy) and have experienced one or
more episodes of SH in the past two years and/or have
subjective impaired awareness of hypoglycaemia (the pa-
tient has no or significantly reduced autonomic symp-
toms when blood glucose drops below 4 mmol/l).
Furthermore, patients should have access to the Internet
and be willing and able to actively attend the three
group meetings.
Patients are excluded from participation when they
meet one or more of the following exclusion criteria:
serious medical co-morbidity (e.g. cancer or dialysis); a
major psychiatric disorder (e.g. bipolar depression or
schizophrenia); established cognitive impairment; sub-
stance abuse; pregnancy; insufficient Dutch language
skills or visual impairments.
Recruitment and planning
In order to take part in our study, clinics need to indi-
cate to be able to include 20 participants. Via posters
and information brochures, the study will be announced
and explained. The diabetes teams in each clinic will
check patients on in—and exclusion criteria. The local
coordinator will collect all informed consent forms and
send those to the study coordinator. Patients will receive
a personal link to the online questionnaires via email.
Then, participants are either enrolled in HypoAware or
will first receive usual care for 6 months, depending on
the clinic at which they are registered. Blinding of
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intervention. Participants receive the online question-
naire again at 2, 4 and 6 months follow-up. After
6 months, our study team will train the diabetes care
teams from the control group. Participants from the
control group can receive the intervention if so wished.
Only the intervention group receives an additional ques-
tionnaire after 12 months. An overview of the study de-
sign and participant flow is provided in Fig. 1.
Interventions
HypoAware
As mentioned earlier, HypoAware is an adapted version
of BGAT. HypoAware was developed in close collabor-
ation with diabetes experts and persons with diabetes.
HypoAware consists of three group sessions of 2.5 h
during four weeks, combined with two online modules
in the weeks between meetings. Topics covered in the
group meetings and online are presented in Table 1.
Groups are led by two trained diabetes professionals and
consist of eight participants; due to the nature of the
intervention these professionals cannot be blinded.
HypoAware aims to improve symptom recognition, risk
awareness, preventive and problem-solving strategies
and coping with (the risk of ) hypoglycaemia. The inter-
vention is guided by the biopsychobehavioural model ofFig. 1 Flow chart of study design and participant flowrisk of severe hypoglycaemia by Linda Gonder-Frederick
and colleagues [6], which describes the effect of behav-
ioural mechanisms, like attention for and attribution of
hypoglycaemia symptoms, on the risk of severe
hypoglycaemia. It also focuses on the usage of ‘internal
cues’ for low blood glucose (physical and mental symp-
toms) and the prediction and prevention of hypoglycaemia
through ‘external cues’ (e.g. the effect of insulin, food in-
take and physical activity). Group sessions are highly inter-
active and aimed at patient-empowerment, in which
patient responsibility and informed decision making is en-
couraged (when appropriate). Group meetings promote
modelling, social reinforcement and sharing of experi-
ences. Partners or other significant others are invited to
the third meeting to discuss their attitudes towards
their own and partners’ responsibilities regarding the
prevention and treatment of hypoglycaemia. The user-
friendly online modules consist of educational texts
and videos, automated exercises, self-tests and personal
diary analyses. Results and progress can be viewed on-
line and printed by participants and trainers and are
discussed in the group meetings. Also, results can be
entered in the participants’ medical file for subsequent
routine visits. More information about the development
and feasibility of HypoAware is published elsewhere
doi: 10.1111/dme.12876.
Table 1 HypoAware: development and pilot-study of a brief and partly web-based psychoeducational group intervention for adults
with type 1 and insulin-treated type 2 diabetes and problematic hypoglycaemia
Group meetings Online environment
1b) First group meeting: introduction, discussion of goals, ‘internal cues’ of
hypoglycaemia and impaired hypoglycaemia awareness, ‘feel-exercise’ to
scan for internal cues, psychobehavioural mechanisms in the treatment of
hypoglycaemia, explanation of homework—the diary, estimation-grid an
internal cues. (2.5 h)
1a) Self-test for goal-setting
1c) Homework: two weeks of keeping a blood glucose estimation and
symptom diary, online education synchronous to topics of first group
meeting plus tips to prevent hypo- and hyperglycaemia and playful tests
to scan for neuroglycopenic symptoms. (1 h)
2a) Second group meeting: discussion of first online diary analysis, influence
of ‘external cues’ on blood glucose level, fear of hypoglycaemia—degree of
worrying about hypoglycaemia and taking precautionary measures versus
risk of hypoglycaemia, explanation of homework—external cues. (2.5 h)
2b) Homework: two weeks of keeping a blood glucose estimation and
symptom diary, online education synchronous to topics of second and
third group meeting plus tips to treat hypoglycaemia, education about
counting carbohydrates, the working of insulin and the effect of exercise,
stress and illness on blood glucose, playful ‘experiments’ with food,
exercise and insulin, a stress reduction exercise and a ‘hypo-simulator’
exercise which show effect of different foods on blood glucose. (1,5 h)
3a) Third group meeting (significant others are invited): introduction of
partners, role of partner versus needs of participant concerning the risk of
hypoglycaemia, discussion of second online diary analysis, discussion of
accomplished goals, setting of specific goals for the action plan, which
will be followed-up on in the next diabetes consultation. (2.5 h)
3b) Self-test for goal-accomplishment and future goal-setting and action plana
End-document with intervention results (self-tests, two diary analyses,
experiment results and action plan) can be printed or digitally saved by
the trainers and participants. Results, remarks and referrals will be entered
in the participants’ medical file.
Table from doi: 10.1111/dme.12876 in adapted form
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Prior to delivering HypoAware, members of the diabetes
teams from the intervention group (two to four members
per clinic) receive a one-day protocolized training by our
study team and are provided with a detailed trainer manual.
Eligible for the training are diabetes nurses, endocrinolo-
gists, diabetes dieticians or medical psychologists with
expertise in diabetes. The training focuses on how to coord-
inate and implement the program and how to lead the
group meetings. The HypoAware approach encourages fu-
ture trainers to stimulate participants in a non-judgmental
and non-directive way to share their experiences and learn
from each other rather than from a tutor. The focus is on
informed decision-making and patient-empowerment.
During the study, trainers are contacted after each ses-
sion, to check for any protocol violations and experienced
difficulties. Trainers can contact the study coordinator to
discuss any questions or problems should they arise.
Control-care as usual
In the first six months, participants of the control group
only have access to care as normally provided by their
diabetes team. There is no specific protocol or guideline
available to guide care for people with diabetes and prob-
lematic hypoglycaemia other than the national guidelines
[7]. According to survey data by our research group
(unpublished), patients can expect to receive one to three
extra consultations with the diabetes nurse and/ordietician and additional telephone/email contact. The ap-
pointments with the diabetes nurse focus on adjusting
glucose-lowering medication and examining blood glu-
cose patterns. Often (temporary) higher blood glucose
targets are advised. The dietician helps with adjusting the
carbohydrate-insulin ratio.
After the six months follow-up, participants in the
control group can receive HypoAware.
Outcomes
All measures mentioned below will be administered at
the start of the study, and 2, 4 and 6 months after inclu-
sion through web-based questionnaires. The clinical data
will be collected from the medical files by the local co-
ordinator from each clinic. The intervention group re-
ceives an additional measurement at 12 months to
analyse long-term effects over time.
Primary outcome
The primary outcome is self-reported frequency of severe
hypoglycaemia after 6 months, defined as “a hypoglycaemic
event serious enough to require the help of another person”.
Secondary health-related outcomes
 Self-reported frequency of mild hypoglycaemia per
week is formulated as “a hypoglycaemic event not
serious enough to require the help of another
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number of blood glucose measurements in the past
week, how many of those measurements were below
4 mmol/l and how many times they felt low without
confirming it with a test.
 Hypoglycaemia awareness will be evaluated using
the validated Gold score [8] and Clarke
questionnaire [9].
 Fear of hypoglycaemia(both worrying and avoidance
behaviour) will be measured using the revised
Hypoglycaemia Fear Survey (HFS-II) [10].
 Diabetes-related distress will be assessed with the
short-form Problem Areas In Diabetes scale
(PAID-5) [11].
 Anxiety and depression, will be assessed with the
Hospital Anxiety and Depression Scale (HADS) [12].
 Diabetes-specific self-efficacy will be evaluated with
the Confidence In Diabetes Self-care (CIDS) [13].
 Health-related quality of life will be measured using the
EuroQol 5-dimensional 5-level version (EQ-5D-5 L)
and the visual analogue scale (EQ-5D VAS) [14].
 Demographics will be measured at baseline, along
with the following clinical data from the medical file:
glycosylated haemoglobin (HbA1c), type of diabetes,
treatment regimen, diabetes duration, diabetes-related
complications, and co-morbidities.
Cost-effectiveness outcomes
The obtained EQ-5D-5 L scores [14] will be used to cal-
culate utilities according to the Dutch tariff. For the
economic evaluation, costs will be measured using the
TiC-P questionnaire [15] with a recall period of 2 months.
Costs that will be included are direct costs of healthcare
utilization (e.g., hospital admissions, outpatient visits and
calls, emergency room visits, ambulance transfers, medi-
cation and medical supply usage), costs of informal care,
and indirect costs (productivity loss due to work absentee-
ism from paid and unpaid work). If available, Dutch guide-
line prices will be used to value resource use. Medication
use will be valued using prices of the Royal Dutch Society
for Pharmacy. Lost productivity costs will be calculated
according to the friction cost approach (friction period
154 days) using the mean age and sex-specific income of
the Dutch population. According to the friction cost ap-
proach a sick employee is replaced after a certain amount
of time (the friction period) after which there are no lost
productivity costs anymore. All costs will be adjusted to
the year in which most data is collected using consumer
price indices.
Process outcomes
We will assess participants’ and trainers’ compliance
with the intervention via contact with the trainers after
every group meeting. We will determine the number ofmeetings followed by every participant and protocol vio-
lations. We will also use information from the online en-
vironment to determine whether participants completed
the online assignments.
Sample size
A power analysis was performed to determine the sample
size using STATA 11.2 (Statacorp, Texas, USA). We based
our effect size on a randomised controlled trial of the inter-
vention BGAT that showed the most conservative effect
[16]. Mean frequency of severe hypoglycaemia at baseline
was 1.61 (SD 3.49) and 0.13 (SD 0.33) 6 months post
BGAT. The control condition (group education about dia-
betes guided by a physician) scored 1.76 (SD 3.71) at base-
line and 1.07 (SD 2.85) after 6 months. This implicated
that, with 3 follow-up measurements and ρ = 0.6, the alpha
set at 0.05, a power of 80 %, and adjusting for clustering
within 8 diabetes teams with an ICC of 0.01 as de-
scribed by Twisk [17], we need 62 patients per group
(total n = 124) to perform our primary analyses. Antici-
pating a 20 % loss to follow-up, we aim to randomise
77 patients per group (total n = 154).
Statistical analyses
Data will be analyzed based on the intention-to-treat
principle. We will use a multilevel generalized linear
model for count data to assess the effectiveness of HypoA-
ware on the frequency of severe hypoglycaemia, while
allowing for clustering of events in patients and clinics.
Secondary outcomes will also be assessed using multilevel
(generalized) linear models in case of continuous, count
or ordinal outcome variables. Generalized Estimation
Equations (GEE) will be used to analyse dichotomous out-
come variables.
Economic evaluation
Both a cost-effectiveness and cost-utility analysis will be
performed with a time horizon of 6 months. Therefore,
discounting is not necessary.
Societal costs will be related to the following effect mea-
sures in the economic evaluation: 1) Frequency of severe
hypoglycaemia; 2) Quality-adjusted life-years (QALYs),
calculated using the area-under-the-curve method with
linear interpolation between time points. QALYs will be
based on the Dutch tariff for the EQ-5D-5 L.
The analysis will be done according to the intention-
to-treat principle. Missing cost and effect data will be
imputed using multiple imputation techniques. Adjust-
ment for confounders and effect modifiers will be done,
if necessary. Sensitivity analyses will be performed to as-
sess the robustness of the results using different assump-
tions regarding costs.
Incremental cost-effectiveness ratios (ICERs) will be
calculated by dividing the difference in mean total costs
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ference in mean effects. Bootstrapping with 5000 replica-
tions will be used to estimate 95 % confidence intervals
around cost differences and the uncertainty surrounding
the ICERs. Uncertainty will be graphically presented on
cost-effectiveness planes. Cost-effectiveness acceptability
curves showing the probability that the intervention is
cost-effective in comparison with usual care for a range of
different ceiling ratios will also be estimated.
Discussion
Existing psycho-educational interventions aimed at re-
ducing hypoglycaemia are effective, but demanding on
the recourses of the clinics, health professionals and
people with diabetes. We propose to study the costs and
effects of our brief psycho-educational intervention,
HypoAware, in comparison to care as usual in a cluster-
randomised RCT.
A potential limitation of this study could be our rela-
tively short follow-up period of 6 months to compare
group effects. It is possible that the potential benefits of
HypoAware will not yet be fully visible after 6 months, be-
cause severe hypoglycaemia occurs on average 1.0 to 1.7
times a year [18]. However, in this specific group with im-
paired awareness of hypoglycaemia and/or recent severe
hypoglycaemia, occurrence of severe hypoglycaemia is
higher than in a non-selected group of diabetes patients.
To study the longer term effects, we do measure the inter-
vention group at an additional 12 months. It would not be
ethical to withhold the participants in the control group
our new intervention for a year, since no other structured
care is available for these patients.
Another possible limitation is that we rely on self-report
of hypoglycaemia since validation of hypoglycaemic epi-
sodes, for example by means of continuous glucose moni-
toring technology, was not feasible. Self-reported frequency
of severe hypoglycaemia for the past year (and the past
week for mild hypoglycaemia) seems reliable, although an
underestimation of severe hypoglycaemia seems likely in
case of sub-groups with a high frequency of severe
hypoglycaemia [19]. In our study, we will inquire about the
previous six months in case of severe hypoglycaemia.
It is not possible to blind patients and caregivers to
the randomisation due to the nature of the study; how-
ever, since both groups receive HypoAware, we can as-
sume similar expectancies in both groups.
Overall, this study will provide valuable information
about the effectiveness and cost-effectiveness of a com-
bined group and online psycho-educational intervention
to reduce and prevent episodes of severe hypoglycaemia
and other hypoglycaemia-related problems in type 1 and
type 2 insulin-treated diabetes patients, both from a clin-
ical and societal perspective. Since, in the current eco-
nomic climate, care has to be as effective as possible, foras little money as possible, interventions have a greater
chance of being implemented if cost/benefit trade-off is
favourable. Studying our intervention will also contrib-
ute to the evidence of the effect of downsizing relatively
‘intensive’ and costly interventions and complementing a
group format with the Internet. This format could be ap-
plied to other interventions to improve implementation,
while maintaining quality and high standards of care.
If HypoAware is proven cost-effective, it will be adopted
and promoted by the Dutch Diabetes Federation as a sup-
portive tool for managing recurrent hypoglycaemia.
Trial status
This study is in the process of data collection. We ex-
pect the first trial results in the fall of 2015.
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